Seasoned Industry Advisor Brings Deep Domain Expertise and Operational Experience
October 15, 2015, Wellesley, MA and Reston, VA Outcome Capital (outcomecapital.wpengine.com), an investment banking firm that serves middle market growth companies in life sciences, healthcare services, software and IT markets, today announced the firm has hired Donald D. Haut as a Senior Advisor for its rapidly growing Boston area-based life sciences practice.
Dr. Haut is Managing Director for Haut Capital, which he started in 2014, and currently serves on the Board of Directors for three health care companies: MiMecore Therapeutics, Arthrosurface, and Xiros. Prior, he was Vice President for New Business Ventures at The Medicines Company, where he was responsible for leading that company’s deal to license Alnylam’s PCSK9 inhibitor. Previously, he was the Senior Vice President for Strategy and Business Development at Smith and Nephew’s Advanced Surgical Devices Division, where he was responsible for all strategy development, M&A and licensing activities, and also built and ran Smith & Nephew’s Women’s Health business. Dr. Haut also previously held similar roles at 3M, JSB Partners and McKinsey and Company. He obtained his MBA at Washington University’s Olin School of Business, his PhD in Molecular Biology at the University of Missouri-Columbia, and his undergraduate degree at the College of Wooster.
“Over the course of my career leading transactions in the life sciences industry, I’ve had many opportunities to witness the thoughtfulness and integrity with which the team at Outcome Capital conducts their business,” said Dr. Haut. “I was delighted to be asked to join this respected team, and especially drawn to their approach of building long-term, lasting value for clients.”
Dr. Oded Ben-Joseph, Managing Director at Outcome Capital commented: “Our strategic approach to value enhancement, including the ability to carve out a clear path to liquidity for our clients, relies on the significant corporate and operational experience of our life sciences group. We are delighted to welcome Don to the Outcome team. His deep domain expertise across multiple disciplines in the pharmaceutical, biotech, and medical device segments, coupled with his transactional expertise, is unique and will complement Outcome’s entrepreneurial culture to the benefit of our clients.”
About Outcome Capital
Outcome Capital is a unique investment banking firm that provides middle-market growth companies in the life sciences, healthcare services and technology markets with a value-added client-centric approach to merger, acquisition and corporate finance advisory services. The firm utilizes its proven approach to value enhancement by assisting boards and management teams in navigating both the financial and strategic markets and in implementing the best path for success. Outcome Capital’s strength stems from its unique ability to draw on its wide range of operational, strategic and private equity experience, its expertise across the value building life-cycle, and its broad industry relationships. The professionals at Outcome Capital take pride in their ability to help their clients to make well-informed strategic decisions and recognize the full value created by their vision. For more information, visit: outcomecapital.wpengine.com
BOSTON–(BUSINESS WIRE)–Outcome Capital, a highly specialized life sciences and healthcare advisory and investment banking firm, today announced that ELIOS Vision, Inc. completed a growth financing round to support its European commercialization. Outcome Capital served as the exclusive strategic and financial advisor to the company. ELIOS’ implant-free, minimally invasive Excimer Laser Trabeculostomy glaucoma procedure is approved […]Read More
Outcome Capital Life Science Market Pulse July 2022 Click to view our LifeSciences Pulse NewsletterDownload